185 related articles for article (PubMed ID: 31241783)
1. Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins.
Ji L; Liu C; Yuan Y; Gao H; Tang ZX; Yang Z; Liu ZT; Jiang GH
Fundam Clin Pharmacol; 2020 Feb; 34(1):4-10. PubMed ID: 31241783
[TBL] [Abstract][Full Text] [Related]
2. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton.
Benhammou JN; Qiao B; Ko A; Sinnett-Smith J; Pisegna JR; Rozengurt E
Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G239-G250. PubMed ID: 37366601
[TBL] [Abstract][Full Text] [Related]
4. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
5. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
[TBL] [Abstract][Full Text] [Related]
6. β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.
Tocci P; Cianfrocca R; Di Castro V; Rosanò L; Sacconi A; Donzelli S; Bonfiglio S; Bucci G; Vizza E; Ferrandina G; Scambia G; Tonon G; Blandino G; Bagnato A
Nat Commun; 2019 Jul; 10(1):3196. PubMed ID: 31324767
[TBL] [Abstract][Full Text] [Related]
7. Statins inhibit blastocyst formation by preventing geranylgeranylation.
Alarcon VB; Marikawa Y
Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
[TBL] [Abstract][Full Text] [Related]
8. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
10. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
11. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
[TBL] [Abstract][Full Text] [Related]
12. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Sarrabayrouse G; Pich C; Teiti I; Tilkin-Mariame AF
Int J Cancer; 2017 Feb; 140(4):747-755. PubMed ID: 27616679
[TBL] [Abstract][Full Text] [Related]
13. Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy.
Riganti C; Aldieri E; Doublier S; Bosia A; Ghigo D
Mini Rev Med Chem; 2008 Jun; 8(6):609-18. PubMed ID: 18537716
[TBL] [Abstract][Full Text] [Related]
14. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
Tutuska K; Parrilla-Monge L; Di Cesare E; Nemajerova A; Moll UM
Cell Death Dis; 2020 Apr; 11(4):274. PubMed ID: 32332697
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of statin-induced rhabdomyolysis.
Sakamoto K; Kimura J
J Pharmacol Sci; 2013; 123(4):289-94. PubMed ID: 24257439
[TBL] [Abstract][Full Text] [Related]
17. Rho GTPases: promising cellular targets for novel anticancer drugs.
Fritz G; Kaina B
Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of statins: A focus on cancer.
Ahmadi M; Amiri S; Pecic S; Machaj F; Rosik J; Łos MJ; Alizadeh J; Mahdian R; da Silva Rosa SC; Schaafsma D; Shojaei S; Madrakian T; Zeki AA; Ghavami S
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165968. PubMed ID: 32927022
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol and beyond - The role of the mevalonate pathway in cancer biology.
Göbel A; Rauner M; Hofbauer LC; Rachner TD
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188351. PubMed ID: 32007596
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations.
Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S
Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
